Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

NCT05676450 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05676450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Lead sponsor
M.D. Anderson Cancer Center
Phase
Not applicable
Overall status
Recruiting
Start date
February 23, 2023
Completion date
August 31, 2026
Enrollment
517 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma